Human genes involved in hepatitis B virus infection

World Journal of Gastroenterology

Volumn 20, Issue 24, 2014, Pages 7696-7706

  Zeng, Zheng ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Clearance; Epidemiology; Genetic; Hepatitis B virus; Hepatocellular carcinoma; Natural history; Outcome; Persistance; Polymorphism

Indexed keywords

CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR5; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULYSIN; HLA A ANTIGEN; HLA B35 ANTIGEN; HLA C ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 28B; MANNOSE BINDING LECTIN; OSTEOPONTIN; RANTES; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D; GENETIC MARKER;

ARTICLE; CANCER RISK; CD4+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; GENE; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HLA SYSTEM; HUMAN; HUMAN GENETICS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; META ANALYSIS (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; PERSISTENT VIRUS INFECTION; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; VIRAL CLEARANCE; VIRUS CARRIER; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; HOST PATHOGEN INTERACTION; PATHOGENICITY; PHENOTYPE; PROGNOSIS; RISK FACTOR; VIROLOGY;

GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS B; HEPATITIS B VIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; PHENOTYPE; PROGNOSIS; RISK FACTORS;

EID: 84903189190     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i24.7696     Document Type: Article

References (86)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107 [PMID: 14996343 DOI: 10.1046/j.1365-2893.2003.00487.x]
2. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60 [PMID: 7612225 DOI: 10.1146/annurev.iy.13.040195.000333]
3. Chisari FV. Cytotoxic T cells and viral hepatitis. J Clin Invest 1997; 99: 1472-1477 [PMID: 9119989 DOI: 10.1172/JCI119308]
4. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, Cavalli A, Urbani S, Boehme R, Panebianco R, Fiaccadori F, Ferrari C. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001; 33: 963-971 [PMID: 11283861 DOI: 10.1053/jhep.2001.23045]
5. Mayerat C, Mantegani A, Frei PC. Does hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection? J Viral Hepat 1999; 6: 299-304 [PMID: 10607244 DOI: 10.1046/j.1365-2893.1999.00174.x]
6. Zheng JX, Zeng Z, Zheng YY, Yin SJ, Zhang DY, Yu YY, Wang F. Role of hepatitis B virus base core and precore/ core promoter mutations on hepatocellular carcinoma in untreated older genotype C Chinese patients. J Viral Hepat 2011; 18: e423-e431 [PMID: 21914059 DOI: 10.1111/ j.1365-2893.2011.01458.x]
7. Zheng J, Zeng Z, Zhang D, Yu Y, Wang F, Pan CQ. Prevalence and significance of Hepatitis B reverse transcriptase mutants in different disease stages of untreated patients. Liver Int 2012; 32: 1535-1542 [PMID: 22882650 DOI: 10.1111/ j.1478-3231.2012.02859.x]
8. Ohnishi K, Iida S, Iwama S, Goto N, Nomura F, Takashi M, Mishima A, Kono K, Kimura K, Musha H, Kotota K, Okuda K. The effect of chronic habitual alcohol intake on the development of liver cirrhosis and hepatocellular carcinoma: relation to hepatitis B surface antigen carriage. Cancer 1982; 49: 672-677 [PMID: 6275976]
9. Frieden TR, Ozick L, McCord C, Nainan OV, Workman S, Comer G, Lee TP, Byun KS, Patel D, Henning KJ. Chronic liver disease in central Harlem: the role of alcohol and viral hepatitis. Hepatology 1999; 29: 883-888 [PMID: 10051493 DOI: 10.1002/hep.510290308]
10. Arico S, Galatola G, Tabone M, Corrao G, Torchio P, Valenti M, De la Pierre M. The measure of life-time alcohol consumption in patients with cirrhosis: reproducibility and clinical relevance. Liver 1995; 15: 202-208 [PMID: 8544643 DOI: 10.1111/j.1600-0676.1995.tb00671.x]
11. Sun Z, Lu P, Gail MH, Pee D, Zhang Q, Ming L, Wang J, Wu Y, Liu G, Wu Y, Zhu Y. Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology 1999; 30: 379-383 [PMID: 10421643 DOI: 10.1002/hep.510300204]
12. Thio CL, Thomas DL, Karacki P, Gao X, Marti D, Kaslow RA, Goedert JJ, Hilgartner M, Strathdee SA, Duggal P, O' Brien SJ, Astemborski J, Carrington M. Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection. J Virol 2003; 77: 12083-12087 [PMID: 14581545 DOI: 10.1128/JVI.77.22.12083-12087.2003]
13. Wu YF, Wang LY, Lee TD, Lin HH, Hu CT, Cheng ML, Lo SY. HLA phenotypes and outcomes of hepatitis B virus infection in Taiwan. J Med Virol 2004; 72: 17-25 [PMID: 14635006 DOI: 10.1002/jmv.10557]
14. Albayrak A, Ertek M, Tasyaran MA, Pirim I. Role of HLA allele polymorphism in chronic hepatitis B virus infection and HBV vaccine sensitivity in patients from eastern Turkey. Biochem Genet 2011; 49: 258-269 [PMID: 21188498 DOI: 10.1007/ s10528-010-9404-6]
15. Hu Z, Liu Y, Zhai X, Dai J, Jin G, Wang L, Zhu L, Yang Y, Liu J, Chu M, Wen J, Xie K, Du G, Wang Q, Zhou Y, Cao M, Liu L, He Y, Wang Y, Zhou G, Jia W, Lu J, Li S, Liu J, Yang H, Shi Y, Zhou W, Shen H. New loci associated with chronic hepatitis B virus infection in Han Chinese. Nat Genet 2013; 45: 1499-1503 [PMID: 24162738 DOI: 10.1038/ng.2809]
16. Ramezani A, Hasanjani Roshan MR, Kalantar E, Eslamifar A, Banifazl M, Taeb J, Aghakhani A, Gachkar L, Velayati AA. Association of human leukocyte antigen polymorphism with outcomes of hepatitis B virus infection. J Gastroenterol Hepatol 2008; 23: 1716-1721 [PMID: 18761557 DOI: 10.1111/ j.1440-1746.2008.05482.x]
17. Kummee P, Tangkijvanich P, Poovorawan Y, Hirankarn N. Association of HLA-DRB1*13 and TNF-alpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population. J Viral Hepat 2007; 14: 841-848 [PMID: 18070287 DOI: 10.1111/ j.1365-2893.2007.00880.x]
18. Thursz MR, Kwiatkowski D, Allsopp CE, Greenwood BM, Thomas HC, Hill AV. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med 1995; 332: 1065-1069 [PMID: 7898524 DOI: 10.1056/NEJM199504203321604]
19. Höhler T, Gerken G, Notghi A, Lubjuhn R, Taheri H, Protzer U, Löhr HF, Schneider PM, Meyer zum Büschenfelde KH, Rittner C. HLA-DRB1*1301 and *1302 protect against chronic hepatitis B. J Hepatol 1997; 26: 503-507 [PMID: 9075656]
20. Cho SW, Cheong JY, Ju YS, Oh do H, Suh YJ, Lee KW. Human leukocyte antigen class II association with spontaneous recovery from hepatitis B virus infection in Koreans: analysis at the haplotype level. J Korean Med Sci 2008; 23: 838-844 [PMID: 18955791 DOI: 10.3346/jkms.2008.23.5.838]
21. Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N, Kubo M, Tsunoda T, Kamatani N, Kumada H, Puseenam A, Sura T, Daigo Y, Chayama K, Chantratita W, Nakamura Y, Matsuda K. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009; 41: 591-595 [PMID: 19349983 DOI: 10.1038/ng.348]
22. An P, Winkler C, Guan L, O'Brien SJ, Zeng Z. A common HLA-DPA1 variant is a major determinant of hepatitis B virus clearance in Han Chinese. J Infect Dis 2011; 203: 943-947 [PMID: 21402545 DOI: 10.1093/infdis/jiq154]
23. Guo X, Zhang Y, Li J, Ma J, Wei Z, Tan W, O'Brien SJ. Strong influence of human leukocyte antigen (HLA)-DP gene variants on development of persistent chronic hepatitis B virus carriers in the Han Chinese population. Hepatology 2011; 53: 422-428 [PMID: 21274863 DOI: 10.1002/hep.24048]
24. Cheng HR, Liu CJ, Tseng TC, Su TH, Yang HI, Chen CJ, Kao JH. Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients. PLoS One 2013; 8: e53008 [PMID: 23326374 DOI: 10.1371/journal.pone.0053008]
25. Yan Z, Tan S, Dan Y, Sun X, Deng G, Wang Y. Relationship between HLA-DP gene polymorphisms and clearance of chronic hepatitis B virus infections: case-control study and meta-analysis. Infect Genet Evol 2012; 12: 1222-1228 [PMID: 22543033 DOI: 10.1016/j.meegid.2012.03.026]
26. Wong DK, Watanabe T, Tanaka Y, Seto WK, Lee CK, Fung J, Lin CK, Huang FY, Lai CL, Yuen MF. Role of HLA-DP polymorphisms on chronicity and disease activity of hepatitis B infection in Southern Chinese. PLoS One 2013; 8: e66920 [PMID: 23825586 DOI: 10.1371/journal.pone.0066920]
27. Li J, Yang D, He Y, Wang M, Wen Z, Liu L, Yao J, Matsuda K, Nakamura Y, Yu J, Jiang X, Sun S, Liu Q, Jiang X, Song Q, Chen M, Yang H, Tang F, Hu X, Wang J, Chang Y, He X, Chen Y, Lin J. Associations of HLA-DP variants with hepatitis B virus infection in southern and northern Han Chinese populations: a multicenter case-control study. PLoS One 2011; 6: e24221 [PMID: 21904616 DOI: 10.1371/journal.pone.0024221]
28. Hu L, Zhai X, Liu J, Chu M, Pan S, Jiang J, Zhang Y, Wang H, Chen J, Shen H, Hu Z. Genetic variants in human leukocyte antigen/DP-DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development. Hepatology 2012; 55: 1426-1431 [PMID: 22105689 DOI: 10.1002/hep.24799]
29. Nishida N, Sawai H, Matsuura K, Sugiyama M, Ahn SH, Park JY, Hige S, Kang JH, Suzuki K, Kurosaki M, Asahina Y, Mochida S, Watanabe M, Tanaka E, Honda M, Kaneko S, Orito E, Itoh Y, Mita E, Tamori A, Murawaki Y, Hiasa Y, Sakaida I, Korenaga M, Hino K, Ide T, Kawashima M, Mawatari Y, Sageshima M, Ogasawara Y, Koike A, Izumi N, Han KH, Tanaka Y, Tokunaga K, Mizokami M. Genomewide association study confirming association of HLADP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. PLoS One 2012; 7: e39175 [PMID: 22737229 DOI: 10.1371/journal.pone.0039175]
30. O'Brien TR, Kohaar I, Pfeiffer RM, Maeder D, Yeager M, Schadt EE, Prokunina-Olsson L. Risk alleles for chronic hepatitis B are associated with decreased mRNA expression of HLA-DPA1 and HLA-DPB1 in normal human liver. Genes Immun 2011; 12: 428-433 [PMID: 21346778 DOI: 10.1038/ gene.2011.11]
31. Thomas R, Thio CL, Apps R, Qi Y, Gao X, Marti D, Stein JL, Soderberg KA, Moody MA, Goedert JJ, Kirk GD, Hoots WK, Wolinsky S, Carrington M. A novel variant marking HLADP expression levels predicts recovery from hepatitis B virus infection. J Virol 2012; 86: 6979-6985 [PMID: 22496224 DOI: 10.1128/JVI.00406-12]
32. Thio CL, Carrington M, Marti D, O'Brien SJ, Vlahov D, Nelson KE, Astemborski J, Thomas DL. Class II HLA alleles and hepatitis B virus persistence in African Americans. J Infect Dis 1999; 179: 1004-1006 [PMID: 10068598 DOI: 10.1086/314684]
33. Almarri A, Batchelor JR. HLA and hepatitis B infection. Lancet 1994; 344: 1194-1195 [PMID: 7934542 DOI: 10.1016/S01406736(94)90510-X]
34. Mbarek H, Ochi H, Urabe Y, Kumar V, Kubo M, Hosono N, Takahashi A, Kamatani Y, Miki D, Abe H, Tsunoda T, Kamatani N, Chayama K, Nakamura Y, Matsuda K. A genomewide association study of chronic hepatitis B identified novel risk locus in a Japanese population. Hum Mol Genet 2011; 20: 3884-3892 [PMID: 21750111 DOI: 10.1093/hmg/ddr301]
35. Fletcher GJ, Samuel P, Christdas J, Gnanamony M, Ismail AM, Anantharam R, Eapen CE, Chacko MP, Daniel D, Kannangai R, Abraham P. Association of HLA and TNF polymorphisms with the outcome of HBV infection in the South Indian population. Genes Immun 2011; 12: 552-558 [PMID: 21593777 DOI: 10.1038/gene.2011.32]
36. Corrêa Bde M, Lopes EP, Albuquerque Mde F, Dourado L. Association between HLA-DRB1* polymorphisms and hepatitis B infection in a brazilian population. Rev Assoc Med Bras 2011; 58: 537-542 [PMID: 23090223 DOI: 10.1590/ S0104-42302012000500009]
37. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 25-36 [PMID: 8574849 DOI: 10.1016/S1074-7613(00)80295-2]
38. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 1993; 177: 557-560 [PMID: 8426126]
39. D'Alfonso S, Richiardi PM. A polymorphic variation in a putative regulation box of the TNFA promoter region. Immunogenetics 1994; 39: 150-154 [PMID: 7903959 DOI: 10.1007/ BF00188619]
40. Mekinian A, Tamouza R, Pavy S, Gestermann N, Ittah M, Mariette X, Miceli-Richard C. Functional study of TNF-α promoter polymorphisms: literature review and meta-analysis. Eur Cytokine Netw 2011; 22: 88-102 [PMID: 21768061 DOI: 10.1684/ecn.2011.0285]
41. Höhler T, Kruger A, Gerken G, Schneider PM, Meyer zum Büschenefelde KH, Rittner C. A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol 1998; 111: 579-582 [PMID: 9528902 DOI: 10.1046/j.1365-2249.1998.00534.x]
42. Cheong JY, Cho SW, Hwang IL, Yoon SK, Lee JH, Park CS, Lee JE, Hahm KB, Kim JH. Association between chronic hepatitis B virus infection and interleukin-10, tumor necrosis factor-alpha gene promoter polymorphisms. J Gastroenterol Hepatol 2006; 21: 1163-1169 [PMID: 16824070 DOI: 10.1111/ j.1440-1746.2006.04304.x]
43. Kim YJ, Lee HS, Yoon JH, Kim CY, Park MH, Kim LH, Park BL, Shin HD. Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection. Hum Mol Genet 2003; 12: 2541-2546 [PMID: 12915457 DOI: 10.1093/hmg/ddg262]
44. Du T, Guo XH, Zhu XL, Li JH, Lu LP, Gao JR, Gou CY, Li Z, Liu Y, Li H. Association of TNF-alpha promoter polymorphisms with the outcomes of hepatitis B virus infection in Chinese Han population. J Viral Hepat 2006; 13: 618-624 [PMID: 16907849 DOI: 10.1111/j.1365-2893.2006.00731.x]
45. Zheng MH, Xiao DD, Lin XF, Wu SJ, Peng MM, Yu XY, Liu WY, Li LF, Shi KQ, Fan YC, Chen YP. The tumour necrosis factor-α-238A allele increases the risk of chronic HBV infection in European populations. J Viral Hepat 2012; 19: e11-e17 [PMID: 22239507 DOI: 10.1111/j.1365-2893.2011.01491.x]
46. Zhang TC, Zhao YQ, Hu GL, Liu XQ, Huang XK. The relationship between tumour necrosis factor-α gene polymorphism and susceptibility and clearance of the persistent hepatitis B virus infection in a Chinese population: a metaanalysis. Clin Microbiol Infect 2014; 20: 227-234 [PMID: 23701172 DOI: 10.1111/1469-0691.12257]
47. Shi KQ, Cai XH, Xiao DD, Wu SJ, Peng MM, Lin XF, Liu WY, Fan YC, Chen YP, Zheng MH. Tumour necrosis factorα-857T allele reduces the risk of hepatitis B virus infection in an Asian population. J Viral Hepat 2012; 19: e66-e72 [PMID: 22239528 DOI: 10.1111/j.1365-2893.2011.01540.x]
48. Martin MP, Qi Y, Goedert JJ, Hussain SK, Kirk GD, Hoots WK, Buchbinder S, Carrington M, Thio CL. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis 2010; 202: 1749-1753 [PMID: 20977343 DOI: 10.1086/657146]
49. Li W, Jiang Y, Jin Q, Shi X, Jin J, Gao Y, Pan Y, Zhang H, Jiang J, Niu J. Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int 2011; 31: 1118-1126 [PMID: 21745278 DOI: 10.1111/j.1478-3231.2011.02507.x]
50. Kim SU, Song KJ, Chang HY, Shin EC, Park JY, Kim do Y, Han KH, Chon CY, Ahn SH. Association between IL28B polymorphisms and spontaneous clearance of hepatitis B virus infection. PLoS One 2013; 8: e69166 [PMID: 23874902 DOI: 10.1371/journal.pone.0069166]
51. Seto WK, Wong DK, Kopaniszen M, Proitsi P, Sham PC, Hung IF, Fung J, Lai CL, Yuen MF. HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B. Clin Infect Dis 2013; 56: 1695-1703 [PMID: 23449268 DOI: 10.1093/cid/ cit121]
52. Kandemir Ö, Fidanci SB, Demir N, Görür A, Tamer L. Chronic hepatitis B and IL28B rs12979860 polymorphism: preliminary study. Mol Biol Rep 2013; 40: 6189-6194 [PMID: 24057245 DOI: 10.1007/s11033-013-2730-0]
53. Lee DH, Cho Y, Seo JY, Kwon JH, Cho EJ, Jang ES, Kwak MS, Cheong JY, Cho SW, Lee JH, Yu SJ, Yoon JH, Lee HS, Kim CY, Shin HD, Kim YJ. Polymorphisms near interleukin 28B gene are not associated with hepatitis B virus clearance, hepatitis B e antigen clearance and hepatocellular carcinoma occurrence. Intervirology 2013; 56: 84-90 [PMID: 23343781 DOI: 10.1159/000342526]
54. Al-Qahtani AA, Al-Anazi MR, Abdo AA, Sanai FM, Al-Hamoudi WK, Alswat KA, Al-Ashgar HI, Khalaf NZ, Viswan NA, Al Ahdal MN. Genetic variation in interleukin 28B and correlation with chronic hepatitis B virus infection in Saudi Arabian patients. Liver Int 2013; Epub ahead of print [PMID: 24118788 DOI: 10.1111/liv.12347]
55. Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, Buster EH, Uitterlinden AG, Hansen BE, Chan HL, Janssen HL. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012; 142: 513-520. e1 [PMID: 22108195 DOI: 10.1053/j.gastro.2011.11.025]
56. Lampertico P, Viganò M, Cheroni C, Facchetti F, Invernizzi F, Valveri V, Soffredini R, Abrignani S, De Francesco R, Colombo M. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 2013; 57: 890-896 [PMID: 22473858 DOI: 10.1002/ hep.25749]
57. Holmes JA, Nguyen T, Ratnam D, Heerasing NM, Tehan JV, Bonanzinga S, Dev A, Bell S, Pianko S, Chen R, Visvanathan K, Hammond R, Iser D, Rusli F, Sievert W, Desmond PV, Bowden DS, Thompson AJ. IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α. J Gastroenterol Hepatol 2013; 28: 861-866 [PMID: 23301835 DOI: 10.1111/ jgh.12110]
58. Miyazoe S, Hamasaki K, Nakata K, Kajiya Y, Kitajima K, Nakao K, Daikoku M, Yatsuhashi H, Koga M, Yano M, Eguchi K. Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am J Gastroenterol 2002; 97: 2086-2092 [PMID: 12190181 DOI: 10.1111/j.1572-0241.2002.05926.x]
59. Peng XM, Huang YS, Ma HH, Gu L, Xie QF, Gao ZL. Inter-leukin-10 promoter polymorphisms are associated with the mode and sequel of HBeAg seroconversion in patients with chronic hepatitis B virus infection. Liver Int 2006; 26: 326-333 [PMID: 16584395 DOI: 10.1111/j.1478-3231.2005.01241.x]
60. Zhang TC, Pan FM, Zhang LZ, Gao YF, Zhang ZH, Gao J, Ge R, Mei Y, Shen BB, Duan ZH, Li X. A meta-analysis of the relation of polymorphism at sites-1082 and-592 of the IL-10 gene promoter with susceptibility and clearance to persistent hepatitis B virus infection in the Chinese population. Infection 2011; 39: 21-27 [PMID: 21246248 DOI: 10.1007/ s15010-010-0075-3]
61. Li N, Gao YF, Zhang TC, Chen P, Li X, Su F. Relationship between interleukin 18 polymorphisms and susceptibility to chronic hepatitis B virus infection. World J Hepatol 2012; 4: 105-109 [PMID: 22489263 DOI: 10.4254/wjh.v4.i3.105]
62. Shin HD, Park BL, Cheong HS, Yoon JH, Kim YJ, Lee HS. SPP1 polymorphisms associated with HBV clearance and HCC occurrence. Int J Epidemiol 2007; 36: 1001-1008 [PMID: 17496055 DOI: 10.1093/ije/dym093]
63. Park GH, Kim KY, Cheong JY, Cho SW, Kwack K. Association of GNLY genetic polymorphisms with chronic liver disease in a Korean population. DNA Cell Biol 2012; 31: 1492-1498 [PMID: 22788687 DOI: 10.1089/dna.2012.1709]
64. Conlon K, Lloyd A, Chattopadhyay U, Lukacs N, Kunkel S, Schall T, Taub D, Morimoto C, Osborne J, Oppenheim J. CD8+ and CD45RA+ human peripheral blood lymphocytes are potent sources of macrophage inflammatory protein 1 alpha, interleukin-8 and RANTES. Eur J Immunol 1995; 25: 751-756 [PMID: 7535702 DOI: 10.1002/eji.1830250319]
65. Biddison WE, Taub DD, Cruikshank WW, Center DM, Connor EW, Honma K. Chemokine and matrix metalloproteinase secretion by myelin proteolipid protein-specific CD8+ T cells: potential roles in inflammation. J Immunol 1997; 158: 3046-3053 [PMID: 9120256]
66. Biddison WE, Kubota R, Kawanishi T, Taub DD, Cruikshank WW, Cen-ter DM, Connor EW, Utz U, Jacobson S. Human T cell leukemia virus type I (HTLV-I)-specific CD8+ CTL clones from patients with HTLV-I-associated neurologic disease secrete proinflammatory cytokines, chemokines, and matrix metalloproteinase. J Immunol 1997; 159: 2018-2025 [PMID: 9257869]
67. Price DA, Sewell AK, Dong T, Tan R, Goulder PJ, Rowland-Jones SL, Phillips RE. Antigen-specific release of beta-chemokines by anti-HIV-1 cytotoxic T lymphocytes. Curr Biol 1998; 8: 355-358 [PMID: 9512422]
68. Wagner L, Yang OO, Garcia-Zepeda EA, Ge Y, Kalams SA, Walker BD, Pasternack MS, Luster AD. Beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Nature 1998; 391: 908-911 [PMID: 9495345 DOI: 10.1038/36129]
69. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Annu Rev Immunol 1997; 15: 675-705 [PMID: 9143704 DOI: 10.1146/annurev.immunol.15.1.675]
70. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392: 565-568 [PMID: 9560152 DOI: 10.1038/33340]
71. Sallusto F, Baggiolini M. Chemokines and leukocyte traffic. Nat Immunol 2008; 9: 949-952 [PMID: 18711431 DOI: 10.1038/ ni.f.214]
72. Ahn SH, Kim do Y, Chang HY, Hong SP, Shin JS, Kim YS, Kim H, Kim JK, Paik YH, Lee KS, Chon CY, Moon YM, Han KH. Association of genetic variations in CCR5 and its ligand, RANTES with clearance of hepatitis B virus in Korea. J Med Virol 2006; 78: 1564-1571 [PMID: 17063508 DOI: 10.1002/ jmv.20739]
73. Suneetha PV, Sarin SK, Goyal A, Kumar GT, Shukla DK, Hissar S. Association between vitamin D receptor, CCR5, TNF-alpha and TNF-beta gene polymorphisms and HBV infection and severity of liver disease. J Hepatol 2006; 44: 856-863 [PMID: 16545485 DOI: 10.1016/j.jhep.2006.01.028]
74. Summerfield JA, Ryder S, Sumiya M, Thursz M, Gorchein A, Monteil MA, Turner MW. Mannose binding protein gene mutations associated with unusual and severe infections in adults. Lancet 1995; 345: 886-889 [PMID: 7707811]
75. Thomas HC, Foster GR, Sumiya M, McIntosh D, Jack DL, Turner MW, Summerfield JA. Mutation of gene of mannose binding protein associated with chronic hepatitis B viral infection. Lancet 1996; 348: 1417-1419 [PMID: 8965590]
76. Yuen MF, Lau CS, Lau YL, Wong WM, Cheng CC, Lai CL. Mannose binding lectin gene mutations are associated with progression of liver disease in chronic hepatitis B infection. Hepatology 1999; 29: 1248-1251 [PMID: 10094971 DOI: 10.1002/hep.510290417]
77. Cheong JY, Cho SW, Lim SK, Shin DH, Yoon SK, Lee JE, Hahm KB, Kim JH. Lack of association between hepatitis B virus infection and polymorphism of mannose-binding lectin gene in Korean population. J Korean Med Sci 2005; 20: 65-69 [PMID: 15716605 DOI: 10.3346/jkms.2005.20.1.65]
78. Höhler T, Wünschel M, Gerken G, Schneider PM, Meyer zum Büschenfelde KH, Rittner C. No association between mannose-binding lectin alleles and susceptibility to chronic hepatitis B virus infection in German patients. Exp Clin Immunogenet 1998; 15: 130-133 [PMID: 9813410 DOI: 10.1159/000019064]
79. Bellamy R, Ruwende C, McAdam KP, Thursz M, Sumiya M, Summerfield J, Gilbert SC, Corrah T, Kwiatkowski D, Whittle HC, Hill AV. Mannose binding protein deficiency is not associated with malaria, hepatitis B carriage nor tuberculosis in Africans. QJM 1998; 91: 13-18 [PMID: 9519208 DOI: 10.1093/qjmed/91.1.13]
80. Thio CL, Mosbruger T, Astemborski J, Greer S, Kirk GD, O' Brien SJ, Thomas DL. Mannose binding lectin genotypes influence recovery from hepatitis B virus infection. J Virol 2005; 79: 9192-9196 [PMID: 15994813 DOI: 10.1128/JVI.79.14.91929196.2005]
81. Xu HD, Zhao MF, Wan TH, Song GZ, He JL, Chen Z. Association between Mannose-binding lectin gene polymorphisms and hepatitis B virus infection: a meta-analysis. PLoS One 2013; 8: e75371 [PMID: 24116040 DOI: 10.1371/journal. pone.0075371]
82. Rook GA, Taverne J, Leveton C, Steele J. The role of gamma-interferon, vitamin D3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis. Immunology 1987; 62: 229-234 [PMID: 3119471]
83. Long KZ, Santos JI. Vitamins and the regulation of the immune response. Pediatr Infect Dis J 1999; 18: 283-290 [PMID: 10093956]
84. Bellamy R, Ruwende C, Corrah T, McAdam KP, Thursz M, Whittle HC, Hill AV. Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. J Infect Dis 1999; 179: 721-724 [PMID: 9952386 DOI: 10.1086/314614]
85. Wu JF, Chen CH, Ni YH, Lin YT, Chen HL, Hsu HY, Chang MH. Toll-like receptor and hepatitis B virus clearance in chronic infected patients: a long-term prospective cohort study in Taiwan. J Infect Dis 2012; 206: 662-668 [PMID: 22740716 DOI: 10.1093/infdis/jis420]
86. Al-Qahtani A, Al-Ahdal M, Abdo A, Sanai F, Al-Anazi M, Khalaf N, Viswan NA, Al-Ashgar H, Al-Humaidan H, Al-Suwayeh R, Hussain Z, Alarifi S, Al-Okail M, Almajhdi FN. Toll-like receptor 3 polymorphism and its association with hepatitis B virus infection in Saudi Arabian patients. J Med Virol 2012; 84: 1353-1359 [PMID: 22825813 DOI: 10.1002/ jmv.23271]